The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious
Diseases Society of America jointly sponsored the development of this guideline for the …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19)
pandemic has attracted interest because of its global rapid spread, clinical severity, high …

Interferon-γ release assays (IGRAs) are now established for the immunodiagnosis of latent
infection with Mycobacterium tuberculosis in many countries. However, the role of IGRAs for …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally
thought to have high mortality rates. However, many cases can be treated with the right …

Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses
to previously acquired Mycobacterium tuberculosis infection without clinical evidence of …

This paper describes an action framework for countries with low tuberculosis (TB) incidence
(<100 TB cases per million population) that are striving for TB elimination. The framework …

Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have
become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid …

Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published as …

Rapid progress has been made in the development of new diagnostic assays for tuberculosis
in recent years. New technologies have been developed and assessed, and are now …

Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of
systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety …